Tags

Type your tag names separated by a space and hit enter

A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome.
Am J Gastroenterol. 2018 09; 113(9):1290-1300.AJ

Abstract

OBJECTIVE

Dietary triggers such as gluten and highly fermentable oligo-, di- and monosaccharides and polyols (FODMAP)-containing foods have been associated with worsening irritable bowel syndrome (IBS) symptoms. However, the true impact of dietary restriction on IBS symptoms has remained unclear. The aim of this study was to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) examining the efficacy of exclusion diets (we focused on low FODMAP and gluten-free diets (GFD)) in IBS.

METHODS

We conducted a search of the literature using the electronic databases MEDLINE (1946 to November 2017), EMBASE (1974 to November 2017), Cochrane Central Register of Controlled Trials (November 2017), and Cochrane Database of Systematic Reviews (2005 to November, 2017) for RCTs of exclusion diets in IBS. Two independent reviewers screened citations and a third reviewer resolved disagreement. Two independent reviewers performed eligibility assessment and data abstraction. For inclusion, RCTs that evaluated an exclusion diet versus an alternative or usual diet and assessed improvement in either global IBS symptoms or abdominal pain were required. Data were synthesized as relative risk of symptoms remaining using a random effects model. Quality of evidence was assessed using GRADE methodology.

RESULTS

A total of 1726 citations were identified. After full-text screening a total of nine studies were eligible for the systematic review. There were two RCTs of a GFD, involving 111 participants. Both selected patients who responded to a GFD and then randomized them to continue the diet or have the diet "spiked" with gluten. A GFD was associated with reduced global symptoms compared with a control diet (RR = 0.42; 95% CI 0.11 to 1.55; I2 = 88%), although this was not statistically significant. There were seven RCTs comparing a low FODMAP diet with various control interventions in 397 participants. A low FODMAP diet was associated with reduced global symptoms compared with control interventions (RR = 0.69; 95% CI 0.54 to 0.88; I2 = 25%). The three RCTS that compared low FODMAP diet with rigorous control diets had the least heterogeneity between studies, but also the least magnitude of effect. The overall quality of the data was "very low" according to GRADE criteria.

CONCLUSIONS

There is insufficient evidence to recommend a GFD to reduce IBS symptoms. There is very low quality evidence that a low FODMAP diet is effective in reducing symptoms in IBS patients.

Authors+Show Affiliations

Division of Gastroenterology, McMaster University, Hamilton, ON, Canada. Leeds Gastroenterology institute, St. James's University Hospital, Leeds, UK. Leeds institute of Biomedical and clinical sciences, university of leeds, leeds, UK. Division of Gastroenterology, university of Michigan health system, Ann Arbor, MI, USA. Mayo clinic, jacksonville, FL, USA. Mayo clinic, Rochester, MN, USA. Division of Gastroenterology and hepatology, department of Medicine, houston Methodist hospital, houston, TX, USA. Farncombe Family digestive health Research institute, McMaster university, hamilton, ON, canada.Division of Gastroenterology, McMaster University, Hamilton, ON, Canada. Leeds Gastroenterology institute, St. James's University Hospital, Leeds, UK. Leeds institute of Biomedical and clinical sciences, university of leeds, leeds, UK. Division of Gastroenterology, university of Michigan health system, Ann Arbor, MI, USA. Mayo clinic, jacksonville, FL, USA. Mayo clinic, Rochester, MN, USA. Division of Gastroenterology and hepatology, department of Medicine, houston Methodist hospital, houston, TX, USA. Farncombe Family digestive health Research institute, McMaster university, hamilton, ON, canada. Division of Gastroenterology, McMaster University, Hamilton, ON, Canada. Leeds Gastroenterology institute, St. James's University Hospital, Leeds, UK. Leeds institute of Biomedical and clinical sciences, university of leeds, leeds, UK. Division of Gastroenterology, university of Michigan health system, Ann Arbor, MI, USA. Mayo clinic, jacksonville, FL, USA. Mayo clinic, Rochester, MN, USA. Division of Gastroenterology and hepatology, department of Medicine, houston Methodist hospital, houston, TX, USA. Farncombe Family digestive health Research institute, McMaster university, hamilton, ON, canada.Division of Gastroenterology, McMaster University, Hamilton, ON, Canada. Leeds Gastroenterology institute, St. James's University Hospital, Leeds, UK. Leeds institute of Biomedical and clinical sciences, university of leeds, leeds, UK. Division of Gastroenterology, university of Michigan health system, Ann Arbor, MI, USA. Mayo clinic, jacksonville, FL, USA. Mayo clinic, Rochester, MN, USA. Division of Gastroenterology and hepatology, department of Medicine, houston Methodist hospital, houston, TX, USA. Farncombe Family digestive health Research institute, McMaster university, hamilton, ON, canada.Division of Gastroenterology, McMaster University, Hamilton, ON, Canada. Leeds Gastroenterology institute, St. James's University Hospital, Leeds, UK. Leeds institute of Biomedical and clinical sciences, university of leeds, leeds, UK. Division of Gastroenterology, university of Michigan health system, Ann Arbor, MI, USA. Mayo clinic, jacksonville, FL, USA. Mayo clinic, Rochester, MN, USA. Division of Gastroenterology and hepatology, department of Medicine, houston Methodist hospital, houston, TX, USA. Farncombe Family digestive health Research institute, McMaster university, hamilton, ON, canada.Division of Gastroenterology, McMaster University, Hamilton, ON, Canada. Leeds Gastroenterology institute, St. James's University Hospital, Leeds, UK. Leeds institute of Biomedical and clinical sciences, university of leeds, leeds, UK. Division of Gastroenterology, university of Michigan health system, Ann Arbor, MI, USA. Mayo clinic, jacksonville, FL, USA. Mayo clinic, Rochester, MN, USA. Division of Gastroenterology and hepatology, department of Medicine, houston Methodist hospital, houston, TX, USA. Farncombe Family digestive health Research institute, McMaster university, hamilton, ON, canada.Division of Gastroenterology, McMaster University, Hamilton, ON, Canada. Leeds Gastroenterology institute, St. James's University Hospital, Leeds, UK. Leeds institute of Biomedical and clinical sciences, university of leeds, leeds, UK. Division of Gastroenterology, university of Michigan health system, Ann Arbor, MI, USA. Mayo clinic, jacksonville, FL, USA. Mayo clinic, Rochester, MN, USA. Division of Gastroenterology and hepatology, department of Medicine, houston Methodist hospital, houston, TX, USA. Farncombe Family digestive health Research institute, McMaster university, hamilton, ON, canada.Division of Gastroenterology, McMaster University, Hamilton, ON, Canada. Leeds Gastroenterology institute, St. James's University Hospital, Leeds, UK. Leeds institute of Biomedical and clinical sciences, university of leeds, leeds, UK. Division of Gastroenterology, university of Michigan health system, Ann Arbor, MI, USA. Mayo clinic, jacksonville, FL, USA. Mayo clinic, Rochester, MN, USA. Division of Gastroenterology and hepatology, department of Medicine, houston Methodist hospital, houston, TX, USA. Farncombe Family digestive health Research institute, McMaster university, hamilton, ON, canada.Division of Gastroenterology, McMaster University, Hamilton, ON, Canada. Leeds Gastroenterology institute, St. James's University Hospital, Leeds, UK. Leeds institute of Biomedical and clinical sciences, university of leeds, leeds, UK. Division of Gastroenterology, university of Michigan health system, Ann Arbor, MI, USA. Mayo clinic, jacksonville, FL, USA. Mayo clinic, Rochester, MN, USA. Division of Gastroenterology and hepatology, department of Medicine, houston Methodist hospital, houston, TX, USA. Farncombe Family digestive health Research institute, McMaster university, hamilton, ON, canada. Division of Gastroenterology, McMaster University, Hamilton, ON, Canada. Leeds Gastroenterology institute, St. James's University Hospital, Leeds, UK. Leeds institute of Biomedical and clinical sciences, university of leeds, leeds, UK. Division of Gastroenterology, university of Michigan health system, Ann Arbor, MI, USA. Mayo clinic, jacksonville, FL, USA. Mayo clinic, Rochester, MN, USA. Division of Gastroenterology and hepatology, department of Medicine, houston Methodist hospital, houston, TX, USA. Farncombe Family digestive health Research institute, McMaster university, hamilton, ON, canada.

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review

Language

eng

PubMed ID

30046155

Citation

Dionne, Joanna, et al. "A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome." The American Journal of Gastroenterology, vol. 113, no. 9, 2018, pp. 1290-1300.
Dionne J, Ford AC, Yuan Y, et al. A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. Am J Gastroenterol. 2018;113(9):1290-1300.
Dionne, J., Ford, A. C., Yuan, Y., Chey, W. D., Lacy, B. E., Saito, Y. A., Quigley, E. M. M., & Moayyedi, P. (2018). A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. The American Journal of Gastroenterology, 113(9), 1290-1300. https://doi.org/10.1038/s41395-018-0195-4
Dionne J, et al. A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. Am J Gastroenterol. 2018;113(9):1290-1300. PubMed PMID: 30046155.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. AU - Dionne,Joanna, AU - Ford,Alexander C, AU - Yuan,Yuhong, AU - Chey,William D, AU - Lacy,Brian E, AU - Saito,Yuri A, AU - Quigley,Eamonn M M, AU - Moayyedi,Paul, Y1 - 2018/07/26/ PY - 2018/04/10/received PY - 2018/06/18/accepted PY - 2018/7/27/pubmed PY - 2019/9/7/medline PY - 2018/7/27/entrez SP - 1290 EP - 1300 JF - The American journal of gastroenterology JO - Am. J. Gastroenterol. VL - 113 IS - 9 N2 - OBJECTIVE: Dietary triggers such as gluten and highly fermentable oligo-, di- and monosaccharides and polyols (FODMAP)-containing foods have been associated with worsening irritable bowel syndrome (IBS) symptoms. However, the true impact of dietary restriction on IBS symptoms has remained unclear. The aim of this study was to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) examining the efficacy of exclusion diets (we focused on low FODMAP and gluten-free diets (GFD)) in IBS. METHODS: We conducted a search of the literature using the electronic databases MEDLINE (1946 to November 2017), EMBASE (1974 to November 2017), Cochrane Central Register of Controlled Trials (November 2017), and Cochrane Database of Systematic Reviews (2005 to November, 2017) for RCTs of exclusion diets in IBS. Two independent reviewers screened citations and a third reviewer resolved disagreement. Two independent reviewers performed eligibility assessment and data abstraction. For inclusion, RCTs that evaluated an exclusion diet versus an alternative or usual diet and assessed improvement in either global IBS symptoms or abdominal pain were required. Data were synthesized as relative risk of symptoms remaining using a random effects model. Quality of evidence was assessed using GRADE methodology. RESULTS: A total of 1726 citations were identified. After full-text screening a total of nine studies were eligible for the systematic review. There were two RCTs of a GFD, involving 111 participants. Both selected patients who responded to a GFD and then randomized them to continue the diet or have the diet "spiked" with gluten. A GFD was associated with reduced global symptoms compared with a control diet (RR = 0.42; 95% CI 0.11 to 1.55; I2 = 88%), although this was not statistically significant. There were seven RCTs comparing a low FODMAP diet with various control interventions in 397 participants. A low FODMAP diet was associated with reduced global symptoms compared with control interventions (RR = 0.69; 95% CI 0.54 to 0.88; I2 = 25%). The three RCTS that compared low FODMAP diet with rigorous control diets had the least heterogeneity between studies, but also the least magnitude of effect. The overall quality of the data was "very low" according to GRADE criteria. CONCLUSIONS: There is insufficient evidence to recommend a GFD to reduce IBS symptoms. There is very low quality evidence that a low FODMAP diet is effective in reducing symptoms in IBS patients. SN - 1572-0241 UR - https://www.unboundmedicine.com/medline/citation/30046155/A_Systematic_Review_and_Meta_Analysis_Evaluating_the_Efficacy_of_a_Gluten_Free_Diet_and_a_Low_FODMAPs_Diet_in_Treating_Symptoms_of_Irritable_Bowel_Syndrome_ L2 - https://Insights.ovid.com/pubmed?pmid=30046155 DB - PRIME DP - Unbound Medicine ER -